Ignite Creation Date:
2024-05-06 @ 2:34 AM
Last Modification Date:
2024-10-26 @ 11:20 AM
Study NCT ID:
NCT02076646
Status:
UNKNOWN
Last Update Posted:
2022-04-14
First Post:
2014-02-24
Brief Title:
A Phase III Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Sponsor:
Philogen SpA
Organization:
Philogen SpA
Organization Data
Organization:
Philogen SpA
Class:
INDUSTRY
Study ID:
PH-L19IL2DTIC-04-12
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Philogen SpA
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None